What is Regorafenib?

Regorafenib, also known as Stivarga , was developed by Bayer in Germany and is a multi-target tyrosine kinase inhibitor . It is currently used to treat:

• Advanced metastatic colorectal cancer (mCRC)
• Gastrointestinal stromal tumors (GIST)
• Hepatocellular carcinoma (HCC)

Usage and accessibility in China

Regorafenib has been registered and approved by the China National Medical Products Administration (NMPA) and has been included in the medical insurance catalog in some provinces and cities. However, for patients who are not covered by medical insurance or need to use the medicine quickly, there is still a great pressure to pay out of pocket.

Some patients choose to obtain a more economical version through Hong Kong and third-party medical platforms , while also paying attention to obtaining formal prescriptions.

Common side effects and risk warnings

Cancer Regi may cause a series of side effects during treatment, including:

• Hand-foot syndrome (HFSR)
• High blood pressure , abnormal heart rate
• Fatigue, diarrhea, loss of appetite
• Abnormal liver function, rash

Patients are advised to monitor their blood pressure and liver and kidney function indicators regularly under the guidance of a doctor, and adjust the dosage or stop the medication in a timely manner if side effects are found.

Comparison of prices in China and abroad

In mainland China hospitals, the price of a box of regorafenib (40 mg x 28 tablets) is about RMB 13,000 - 15,000 . After medical insurance reimbursement, the cost in some areas has dropped to RMB 4,000-6,000.

In Hong Kong , the same specification of drugs are sold at legal pharmacies for about HK$10,000 . Some patients choose to purchase drugs across borders to save costs.

• Regorafenib price in China
• What are the side effects of Cancer Rega
• Regorafenib Hong Kong Drug Purchase
• Bayer's targeted drug regorafenib
• Where can I buy Regorafenib?